Curevo Vaccine is a US-based, clinical stage biotech company dedicated to developing next generation vaccines that bring effectiveness, safety, tolerability, and advanced production capabilities to the market - quickly and efficiently. Partnered with a leading pharma company in Korea, R&D and manufacturing capabilities are strengthened with experts. Curevo's lead product, a sub-unit Herpes Zoster (Shingles) Vaccine, is currently in a Phase I clinical trial with interim results showing a promising safety profile and the desired immune responses. The candidate vaccine has been developed for easy scale-up at different production sites to meet global demand. Curevo Vaccine brings excellent clinical operational management and oversight to expedite vaccine candidates to market.